Biopharmaceutical innovation is alive and well. An ever-widening array of product modalities is taking the industry beyond proteins to genes, cells, and tissues — beyond monoclonal antibodies to fragments, bispecifics, and antibody–drug conjugates — beyond live/attenuated vaccines to recombinant proteins, nucleic acids, and immunotherapies. Biosimilar developers are introducing competition that pushes innovators beyond traditional modalities and delivery methods. Authors, reader-survey respondents, and editorial advisors will help us examine trends in regenerative and personalized medicine, fusion proteins, developability assessments, exosomes, and more.

Industry Resources

Gram Scale Transient Antibody Production
and Stable Cell Line Generation
Using Flow Electroporation™ Technology

Get the eBook Now